Overview

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Status:
Not yet recruiting

Trial end date:
2022-07-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines